Baseline cGVHD features at the time of ibrutinib initiation
| Characteristic . | N = 270 . |
|---|---|
| Median time from cGVHD diagnosis to ibrutinib start (IQR), d | 556 (232-1030) |
| Ibrutinib starting dose, n (%) | |
| 420 mg | 143 (66%) |
| 140 mg | 42 (19%) |
| 280 mg | 29 (13%) |
| 70 mg | 2 (0.9%) |
| Unknown | 54 |
| Reason for decreased starting dose, n (%) | |
| Drug interaction | 38 (58%) |
| Clinician discretion | 24 (36%) |
| Pediatric use | 4 (6.1%) |
| Unknown | 204 |
| Total pre-ibrutinib agents, n (%) | |
| 1 | 69 (26%) |
| 2 | 81 (30%) |
| 3 | 56 (21%) |
| 5 | 27 (10%) |
| 4 | 26 (9.6%) |
| 6 | 1 (0.4%) |
| 8 | 1 (0.4%) |
| 9 | 1 (0.4%) |
| cGVHD subtype, n (%) | |
| Classic | 122 (61%) |
| Overlap | 79 (39%) |
| Unknown | 69 |
| PLT, ×103/μL | 236 (17, 734) |
| Unknown | 59 |
| Bilirubin, mg/dL | 0.40 (0.10, 42.20) |
| Unknown | 58 |
| KPS (%) | |
| 80%-100% | 151 (72%) |
| <80% | 59 (28%) |
| Unknown | 60 |
| Prednisone dose (mg/kg per day) | 0.21 (0.00, 2.27) |
| Unknown | 65 |
| Organ site involved n (%) | |
| Skin | 202 (75%) |
| Eye | 164 (61%) |
| Mouth | 147 (54%) |
| Joint/fascia | 127 (47%) |
| GI | 70 (26%) |
| Lung | 73 (27%) |
| Liver | 51 (19%) |
| Genital | 19 (7.0%) |
| Other | 12 (4.4%) |
| BOS | 32 (12%) |
| Skin type | |
| Deep sclerosis | 68 (45%) |
| Superficial sclerosis | 43 (28%) |
| Maculopapular rash | 29 (19%) |
| Lichen planus like | 8 (5.3%) |
| Papulosquamous lesions | 4 (2.6%) |
| Unknown | 118 |
| Overall severity | |
| Severe | 112 (53%) |
| Moderate | 88 (42%) |
| Mild | 12 (5.7%) |
| Unknown | 58 |
| Characteristic . | N = 270 . |
|---|---|
| Median time from cGVHD diagnosis to ibrutinib start (IQR), d | 556 (232-1030) |
| Ibrutinib starting dose, n (%) | |
| 420 mg | 143 (66%) |
| 140 mg | 42 (19%) |
| 280 mg | 29 (13%) |
| 70 mg | 2 (0.9%) |
| Unknown | 54 |
| Reason for decreased starting dose, n (%) | |
| Drug interaction | 38 (58%) |
| Clinician discretion | 24 (36%) |
| Pediatric use | 4 (6.1%) |
| Unknown | 204 |
| Total pre-ibrutinib agents, n (%) | |
| 1 | 69 (26%) |
| 2 | 81 (30%) |
| 3 | 56 (21%) |
| 5 | 27 (10%) |
| 4 | 26 (9.6%) |
| 6 | 1 (0.4%) |
| 8 | 1 (0.4%) |
| 9 | 1 (0.4%) |
| cGVHD subtype, n (%) | |
| Classic | 122 (61%) |
| Overlap | 79 (39%) |
| Unknown | 69 |
| PLT, ×103/μL | 236 (17, 734) |
| Unknown | 59 |
| Bilirubin, mg/dL | 0.40 (0.10, 42.20) |
| Unknown | 58 |
| KPS (%) | |
| 80%-100% | 151 (72%) |
| <80% | 59 (28%) |
| Unknown | 60 |
| Prednisone dose (mg/kg per day) | 0.21 (0.00, 2.27) |
| Unknown | 65 |
| Organ site involved n (%) | |
| Skin | 202 (75%) |
| Eye | 164 (61%) |
| Mouth | 147 (54%) |
| Joint/fascia | 127 (47%) |
| GI | 70 (26%) |
| Lung | 73 (27%) |
| Liver | 51 (19%) |
| Genital | 19 (7.0%) |
| Other | 12 (4.4%) |
| BOS | 32 (12%) |
| Skin type | |
| Deep sclerosis | 68 (45%) |
| Superficial sclerosis | 43 (28%) |
| Maculopapular rash | 29 (19%) |
| Lichen planus like | 8 (5.3%) |
| Papulosquamous lesions | 4 (2.6%) |
| Unknown | 118 |
| Overall severity | |
| Severe | 112 (53%) |
| Moderate | 88 (42%) |
| Mild | 12 (5.7%) |
| Unknown | 58 |
IQR, interquartile range; PLT, platelets.